234 related articles for article (PubMed ID: 8665516)
1. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
[TBL] [Abstract][Full Text] [Related]
2. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage.
Holden JA; Wall ME; Wani MC; Manikumar G
Arch Biochem Biophys; 1999 Oct; 370(1):66-76. PubMed ID: 10496978
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of topoisomerase I function by coralyne and 5,6-dihydrocoralyne.
Wang LK; Rogers BD; Hecht SM
Chem Res Toxicol; 1996; 9(1):75-83. PubMed ID: 8924619
[TBL] [Abstract][Full Text] [Related]
4. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives.
Riou JF; Helissey P; Grondard L; Giorgi-Renault S
Mol Pharmacol; 1991 Nov; 40(5):699-706. PubMed ID: 1658605
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.
Sugimoto Y; Tsukahara S; Oh-hara T; Liu LF; Tsuruo T
Cancer Res; 1990 Dec; 50(24):7962-5. PubMed ID: 2174738
[TBL] [Abstract][Full Text] [Related]
7. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
[TBL] [Abstract][Full Text] [Related]
8. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
9. Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons.
Makhey D; Gatto B; Yu C; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem; 1996 Jun; 4(6):781-91. PubMed ID: 8818227
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
11. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
12. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
13. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
16. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.
Bendetz-Nezer S; Gazit A; Priel E
Mol Pharmacol; 2004 Sep; 66(3):627-34. PubMed ID: 15322255
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase I-mediated formation of structurally modified DNA duplexes. Effects of metal ions and topoisomerase I inhibitors.
Wang X; Henningfeld KA; Hecht SM
Biochemistry; 1998 Feb; 37(8):2691-700. PubMed ID: 9485420
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase inhibitors as anticancer agents: a patent update.
Khadka DB; Cho WJ
Expert Opin Ther Pat; 2013 Aug; 23(8):1033-56. PubMed ID: 23611704
[TBL] [Abstract][Full Text] [Related]
20. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Jobson A; Gilroy KL; Curtis H; Padget K; Austin CA
J Nat Prod; 2007 Dec; 70(12):1884-8. PubMed ID: 18076140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
